

Asger Lund

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761255/publications.pdf>

Version: 2024-02-01

48
papers

2,040
citations

331538

21
h-index

254106

43
g-index

49
all docs

49
docs citations

49
times ranked

2741
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 221-227.	2.2	5
2	Glucagon Clearance Is Preserved in Type 2 Diabetes. <i>Diabetes</i> , 2022, 71, 73-82.	0.3	6
3	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2022, 186, 207-221.	1.9	3
4	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin â€“ physiology and pharmacology. <i>European Journal of Endocrinology</i> , 2022, 186, R93-R111.	1.9	4
5	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. <i>Diabetes Care</i> , 2022, 45, 1476-1481.	4.3	6
6	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 168-173.	1.8	11
7	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. <i>Diabetes</i> , 2021, 70, 1347-1356.	0.3	9
8	Response to Letter to the Editor from McKee and McGill: â€œGlycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoringâ€. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4307-e4308.	1.8	0
9	Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. <i>Diabetic Medicine</i> , 2021, 38, e14655.	1.2	15
10	Mechanisms in Endocrinology: The physiology of neuronostatin. <i>European Journal of Endocrinology</i> , 2021, 185, R93-R101.	1.9	0
11	Hepatic microbiome in healthy lean and obese humans. <i>JHEP Reports</i> , 2021, 3, 100299.	2.6	15
12	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. <i>Diabetes</i> , 2020, 69, 2619-2629.	0.3	11
13	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa097.	0.1	12
14	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. <i>Diabetologia</i> , 2020, 63, 1285-1298.	2.9	11
15	Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1639-1647.	2.2	3
16	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 313-324.	5.5	39
17	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 588-596.	4.3	38
18	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. <i>Diabetes</i> , 2020, 69, 1090-1099.	0.3	50

#	ARTICLE	IF	CITATIONS
19	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , 2020, 11, 617400.	1.5	25
20	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. <i>Endocrine Connections</i> , 2020, 9, 1221-1232.	0.8	2
21	Extrapancreatic glucagon: Present status. <i>Diabetes Research and Clinical Practice</i> , 2019, 147, 19-28.	1.1	9
22	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4092.	1.8	47
23	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , 2019, 62, 665-675.	2.9	81
24	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2953-2960.	1.8	41
25	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G462-G472.	1.6	162
26	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1937-1943.	2.2	3
27	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 288-294.	1.8	64
28	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , 2018, 93, 217-239.	1.4	94
29	Glucagon-like peptide 1 in health and disease. <i>Nature Reviews Endocrinology</i> , 2018, 14, 390-403.	4.3	304
30	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. <i>Diabetes Care</i> , 2018, 41, 1260-1267.	4.3	13
31	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , 2018, 16, 530-536.	0.5	22
32	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , 2018, 8, e021861.	0.8	3
33	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , 2017, 21, 1452-1460.	2.9	28
34	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. <i>EBioMedicine</i> , 2016, 7, 112-120.	2.7	53
35	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. <i>Medical Hypotheses</i> , 2016, 86, 100-103.	0.8	24
36	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4377-4384.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 692-700.	1.3	14
38	Evidence of Extrapancreatic Glucagon Secretion in Man. <i>Diabetes</i> , 2016, 65, 585-597.	0.3	136
39	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , 2014, 3, 193-199.	0.8	2
40	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. <i>Current Diabetes Reports</i> , 2014, 14, 555.	1.7	96
41	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. <i>Diabetologia</i> , 2014, 57, 1720-1725.	2.9	56
42	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , 2014, 7, 326.	0.6	1
43	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. <i>European Journal of Internal Medicine</i> , 2014, 25, 407-414.	1.0	120
44	Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. <i>Current Medical Research and Opinion</i> , 2012, 28, 731-736.	0.9	13
45	Increased Levels of YKL-40 and Interleukin 6 in Patients With Chronic Pancreatitis and Secondary Diabetes. <i>Pancreas</i> , 2012, 41, 1316-1318.	0.5	14
46	Emerging GLP-1 receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 607-618.	1.0	21
47	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 737-745.	1.8	190
48	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E1038-E1046.	1.8	148